Tag - CGTX

Developments

Cognition, AD consortium initiate Phase 2 START study

Cognition Therapeutics (NASDAQ:CGTX) and the Alzheimer’s Clinical Trials Consortium initiated the first clinical site in the 540-patient Phase 2 START study of CT1812 in adults with early Alzheimer’s disease (AD)...

July 5, 2023

Developments

Cognition posts positive topline Phase 2 results in AD

Cognition Therapeutics (NASDAQ:CGTX) reported topline results from its Phase 2 double-blind, single-crossover SEQUEL study of CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease that met its primary endpoints...

June 28, 2023

Developments

Cognition presents proteomic biomarker data in Alzheimer’s

Cognition Therapeutics (NASDAQ:CGTX) presented results of a meta-analysis from the first cohort of 24 participants in the Phase 2 SHINE trial and the complete dataset from the Phase 1b SPARC studies in adults with mild...

March 28, 2023

Feature

Cognition Therapeutics focused on modifying degenerative disorders

As the recipient of more than $170-million of non-dilutive grant funding, Cognition Therapeutics (NASDAQ:CGTX) is developing disease-modifying medicines for neurodegenerative disorders, such as Alzheimer's disease (AD)...

February 21, 2023

Developments

Cognition completes enrollment in Phase 2 SEQUEL study in AD

Cognition Therapeutics (NASDAQ:CGTX) completed enrollment in the randomized, double-blind Phase 2 SEQUEL study of its CT1812 in 16 adults with mild-to-moderate Alzheimer’s disease. The study was designed to assess...

February 9, 2023

Markets

Cantor starts Cognition at OW; PT $12

Cantor Fitzgerald launched coverage of Cognition Therapeutics (NASDAQ:CGTX) with an “overweight” rating and 12-month price target of $12. The stock closed at $1.74 on Sept. 28. Cognition is a neuro-innovator leveraging...

September 29, 2022

Tag - CGTX

Cognition, AD consortium initiate Phase 2 START study

Cognition posts positive topline Phase 2 results in AD

Cognition presents proteomic biomarker data in Alzheimer’s

Cognition Therapeutics focused on modifying degenerative disorders

Cognition completes enrollment in Phase 2 SEQUEL study in AD

Cantor starts Cognition at OW; PT $12

General

More